Roivant Sciences(US:ROIV) ZACKS·2026-02-06 14:15分组1 - Roivant Sciences Ltd. reported a quarterly loss of $0.24 per share, better than the Zacks Consensus Estimate of a loss of $0.27, representing an earnings surprise of +9.43% [1] - The company has surpassed consensus EPS estimates two times over the last four quarters [2] - Montes Archimedes Acquisition posted revenues of $2 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 67.32%, compared to year-ago revenues of $9.02 million [2] 分组2 - The stock of Montes Archimedes Acquisition has lost about 2.6% since the beginning of the year, while the S&P 500 has declined by 0.7% [3] - The earnings outlook for Montes Archimedes Acquisition is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters [4] - The estimate revisions trend for Montes Archimedes Acquisition was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock [6] 分组3 - The current consensus EPS estimate for the coming quarter is -$0.28 on $7.3 million in revenues, and -$1.13 on $19.19 million in revenues for the current fiscal year [7] - The Medical - Biomedical and Genetics industry is currently in the top 37% of the Zacks industries, indicating a favorable outlook for stocks in this sector [8] - TScan Therapeutics, Inc., another company in the same industry, is expected to report a quarterly loss of $0.27 per share, with revenues projected to be $4.08 million, up 509% from the year-ago quarter [9]